CRISPR-Cas13a-based diagnostic method for Chlamydia trachomatis from nongonococcal urethritis

Area of Science:

• Molecular Biology
• Biotechnology
• Infectious Disease Diagnostics

Background:

• Chlamydia trachomatis infections require sensitive and accessible screening methods.
• Current diagnostic techniques may be time-consuming or require specialized equipment.
• CRISPR-Cas13a offers a programmable RNA-targeting system with potential diagnostic applications.

Purpose of the Study:

• To develop a routine and rapid screening technique for Chlamydia trachomatis infection.
• To utilize the CRISPR-Cas13a system for sensitive nucleic acid detection.
• To evaluate the performance of the developed CRISPR-Cas13a assay.

Main Methods:

• Development of a diagnostic assay utilizing CRISPR RNA (crRNA) and the Cas13a protein.
• Activation of Cas13a RNase activity upon binding to the target Chlamydia trachomatis sequence.
• Cleavage of an RNA fluorescent probe, leading to signal generation for detection.

Main Results:

• The CRISPR-Cas13a based detection demonstrated a sensitivity of 10 fM.
• Results from the CRISPR-Cas13a method showed a strong correlation with quantitative polymerase chain reaction (qPCR).
• The assay achieved a high degree of correlation (χ² = 81.798, p < 0.001) compared to qPCR.

Conclusions:

• The developed CRISPR-Cas13a method enables Chlamydia trachomatis screening at room temperature.
• The assay provides results within a 2-hour timeframe.
• The technique's affordability and simplicity make it suitable for community hospitals and screening institutions.